Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents

Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents

US Patent 8557808 · Granted Oct 15, 2013

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Microbial hyperswarmers and uses thereof2024
Compounds, compositions, and methods for selectively inhibiting β-glucuronidases2024
PXR agonists and uses thereof for gut barrier dysfunction treatment and preventi2023
Inhibitors of microbial beta-glucuronidase enzymes and uses thereof2022
Microbial hyperswarmers and uses thereof2021
Ferroportin inhibitors2021
Ferroportin inhibitors2021
Heteroaryl SYK inhibitors2021
Gut barrier dysfunction treatment and prevention2021
Microbial hyperswarmers and uses thereof2020
Ferroportin inhibitors2020
Ferroportin inhibitors2019